← All indications
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
Subtype terms (3)
More specific conditions that are subtypes of Osteoarthritis in the MeSH hierarchy.
- Osteoarthritis, Hip
78 drugs (55 approved, 23 experimental)
- Osteoarthritis, Knee
374 drugs (132 approved, 242 experimental)
- Osteoarthritis, Spine
4 drugs (3 approved, 1 experimental)
Drugs by status
Approved for this indication (45)
- diclofenac
- methylprednisolone
- ketoprofen
- urea
- capsaicin
- prednisone
- diflunisal
- etodolac
- human placenta hydrolysate
- glucosamine
- amlodipine
- famotidine
- hydrocortisone
- imotun
- imrecoxib
- meloxicam
- nabumetone
- naproxen
- prasterone
- indomethacin
- lidocaine
- salsalate
- celecoxib
- sulindac
- valdecoxib
- rofecoxib
- menthol
- triamcinolone
- misoprostol
- carprofen
- +15 more
Phase 4 trials (75)
- propofol
- vitamin d3
- heparin
- ceftaroline fosamil
- linezolid
- desmopressin
- human fibrin
- epoetin
- cefazolin
- chondroitin
- ibuprofen
- betamethasone
- duloxetine
- cannabidiol
- ferric carboxymaltose
- folic acid
- gabapentin
- ethanol
- sevoflurane
- liraglutide
- ketorolac
- daptomycin
- iron dextran
- platelet-rich plasma
- leukocytes
- lumiracoxib
- atorvastatin
- colchicine
- ropivacaine
- acetaminophen
- +45 more
Phase 3 trials (56)
- metformin
- hydrocodone
- oxytocin
- astaxanthin
- autologous fat
- polmacoxib
- oxycodone
- zingiber
- doxycycline
- dulaglutide
- fulranumab
- naltrexone
- hydroxychloroquine
- bone marrow derived mesenchymal stem cells
- icosapent ethyl
- tanezumab
- rimabotulinumtoxinB
- pectin
- adalimumab
- platelet rich fibrin
- donepezil
- calcitonin salmon
- fasinumab
- acetylsalicylic acid
- strontium-89
- tocilizumab
- testosterone
- rabeprazole
- tt-173
- cortisone acetate
- +26 more
Phase 2 trials (83)
- denosumab
- 99mtc ec20
- abt-981
- akr 202
- apocynin
- aquamin
- bone autograft
- canakinumab
- apremilast
- ce-224535
- cobiprostone
- odanacatib
- dlx105
- somatropin
- glpg1972
- gw842166
- gz389988
- calcium
- magnesium oxide
- krill oil
- lna043
- ly3016859
- mk-0686
- mk0782
- Dapansutrile
- pf-00592379
- ph-797804
- pla-695
- alendronic acid
- allogeneic hematopoietic stem cells
- +53 more
Phase 1 trials (35)
- montelukast
- vipadenant
- agg-523
- Aspartyl-alanyl-diketopiperazine
- autologous bone graft
- bone morphogenetic protein-2
- gadoteric acid
- medi-578
- ono-4474
- pelubiprofen
- bi 1026706
- relacatib
- zoledronic acid
- art-i02
- chicory root extract
- sc-raav2.5il-1ra
- tj-14
- orphenadrine hydrochloride
- sar-113945
- baclofen
- methylsulfonylmethane
- grapiprant
- t-087
- mrna-1273
- 2-carba-cyclic phosphatidic acid
- bnt162b2
- epicatechin
- allorx stem cells®
- ecc0509
- Mesenchymal Stem Cell Secretome
- +5 more
Other trials (57)
- melatonin
- ringer's lactate
- t4p1001
- amniotic membrane
- autologous protein solution
- art 44
- axs-02
- ketamine
- diphenhydramine
- crespine
- derris scandens benth extracts
- glycyrrhizin
- lanconone
- egg
- vitis vinifera
- ginger
- iloperidone
- ozone
- autologous serum
- inulin
- iodine
- l-alanine
- vitamin c
- paraffin oil
- lactose
- platelets
- glucose
- vitamin k
- pantothenic acid
- black seed oil
- +27 more
Organizations
Organization Involved with Phase 4 Indications (182)
- Government of Turkey
- Napo Pharmaceuticals
- University of Ulsan
- Aarhus University
- People's Liberation Army of China
- GMC Amritsar
- Centre Hospitalier Departemental Vendee
- Tsinghua University
- Mayo Clinic
- Tedec-Meiji Farma, S.A.
- Hengrui Therapeutics, Inc.
- Medical University of Vienna
- Hebrew University
- Artroclinica de Fortaleza
- Janssen Pharmaceutica NV
- University of Nottingham
- Philipps University of Marburg
- University of Auckland
- Hanyang University
- Medical Benefits Fund Australia Pty Ltd
- Rosetrees Trust
- University of New South Wales
- University of Zurich
- Tufts University
- Iberica Co. Ltd.
- Government of Finland
- CHI Health Mercy Hospital
- ZonMw: The Netherlands Organisation for Health Research and Development
- Haemonetics Corporation
- University of Pavia
- +152 more
Organization Involved with Phase 3 Indications (235)
- Teva
- Azidus
- Eurofarma Laboratorios S.A.
- Sterling Research Group, Ltd
- Acri-Phase I, LLC
- Handok Pharmaceuticals Co., Ltd.
- Hallym University
- Eulji University
- Siriraj Hospital
- University of Nice Sophia Antipolis
- Blair Orthopedic Associates, Inc
- Riverside Clinical Research
- Sewon Cellontech Co., Ltd.
- Physician Recommended Nutriceuticals
- Injury Care Medical Center
- Axsome Therapeutics, Inc.
- Universidad Catolica Santiago de Guayaquil
- IBSA Institut Biochimique SA
- Tucson Orthopaedic Institute
- Chengdu University of Traditional Chinese Medicines
- Quality Research Inc
- Clinical Research Solutions
- Taiwan Liposome Company
- Clinical Trials Technology Inc
- Memorial University of Newfoundland
- Drug Studies America
- University of Western Ontario
- Atrium Innovations
- PMG Research
- Zars Pharma Inc.
- +205 more
Organization Involved with Phase 2 Indications (207)
- CaRe Arthritis Ltd.
- Unidad de Cirugía Artroscópica
- MRA Clinical Research
- Astellas
- Université catholique de Louvain
- Guangzhou Four-Leaf Clover HealthTech Co., Ltd.
- Postgraduate Institute of Medical Education and Research
- Neomed Institute
- Eupraxia Pharmaceuticals
- Russian Academy of Medical Sciences
- University of Campinas
- Veristat, Inc.
- VivaTech International, Inc.
- Dalian Medical University
- Kyiv City Clinical Hospital № 6
- University of Chicago
- Stiftung Marie-Lou Ringgenberg Bern
- KPJ Ampang Puteri Specialist Hospital
- Zalicus
- Cubist
- Merck Serono
- Clinica Universidad de Navarra
- Cytopeutics Pte. Ltd.
- Istituto Ortopedico Gaetano Pini
- M.S. Ramaiah Medical College, Bangalore, India
- Marigot Ltd.
- Cu-Tech
- Lundbeck
- University of Cambridge
- OhioHealth
- +177 more
Organization Involved with Phase 1 Indications (63)
- Isfahan University
- Foundation for Physical Medicine and Rehabilitation
- Primus Pharmaceuticals
- CAR-T (Shanghai) Biotechnology Co.,Ltd.
- Personalized Stem Cells, Inc.
- University of Tehran
- Orient Europharma Co., Ltd.
- Peptinov SAS
- Arthrogen
- Regenerative Orthopedics and Sports Medicine
- Emeritus Research
- OliPass Australia Pty Ltd
- The University of Texas, Dallas
- Sandoz
- Q-Med AB
- Bio-Kinetic Clinical Applications
- Aristotle University of Thessaloniki
- Biomet
- Southeast University
- Chinese University of Hong Kong
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Bioheart, Inc.
- Fodor, Peter B, M.D.
- Hospital for Special Surgery, New York
- Hammersmith Medicines Research
- Stemedica
- University of Alabama, Birmingham
- Lund University
- Stem Cells Arabia
- Merck KGaA
- +33 more
Organization Involved with Other Experimental Indications (123)
- Eurofins
- Mater Misericordiae University Hospital
- BioElectronics Corporation
- Arthritis and Osteoporosis Center of Maryland
- Jiaxing TCM Hospital
- University of Argentina
- Orebro University
- Anhui Medical University
- Aestique Medical Center
- Qingdao University
- Global Alliance for Regenerative Medicine
- Neonutra
- University of Southern California
- GARM USA
- Association Nationale de Prevention Medicale
- Cork University Hospital
- Hospital Center of Lanion
- Regeneris Medical
- Vanderbilt University
- Allegiance Health
- Mansoura University
- MIMA Century Research Associates
- Ambrosia - SupHerb Ltd.
- Spar Nord Foundation
- Yerkoy State Hospital
- Toronto Poly Clinic
- United States Army
- Glasgow Caledonian University
- Red Cross Hospital, Hangzhou, China
- Northumbria Healthcare NHS Foundation Trust
- +93 more